Rabeprazole Sodium/Metronidazole/Amoxicillin

雷贝拉唑钠/甲硝唑/阿莫西林

Report date: 2022/04/19 14:27:29

Base Information

Drug NameRabeprazole Sodium/Metronidazole/Amoxicillin
Drug Alias NameRabefine
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > β-lactam antibiotics
Mechanisms of ActionDNA synthesis inhibitorsProton pump inhibitorsBacterial penicillin-binding protein inhibitors
TargetsProton pumpBacterial penicillin-binding protein
Therapy Area/IndicationsHelicobacter pylori infectionPurpura, Thrombocytopenic, IdiopathicStomach Ulcer +[5] 
Global Approved IndicationsHelicobacter pylori infectionPurpura, Thrombocytopenic, IdiopathicStomach Ulcer +[5] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2013/08/15
Country/TerritoryJapan
CombinationsYes AmoxicillinRabeprazole SodiumMetronidazole
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesEisai Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesEisai Co Ltd
Inactive CompaniesN/A
Active IndicationsHelicobacter pylori infectionPurpura, Thrombocytopenic, IdiopathicStomach Ulcer +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeJ01CR02
Related LinksKEGG